Shots:

• Sinovent & SinoMab to receive $12M up front- ~$549M in development- regulatory & commercial milestone along with royalties on net sales of a product
• The agreement will strengthen Everest’s leadership in developing novel therapies for renal disease in Greater China & Asia. The agreement also includes technology transfer of manufacturing process to Everest for the development & commercialization of the product
• XNW1011 is a covalent reversible BTK inhibitor that exhibits high selectivity- PK- robust target engagement & safety profile to support the development based on results from the P-I study. Everest also plans to initiate a P-II trial of XNW1011 for the same indication

  | Ref: Everest | Image: PR Newswire